Israel Approves Tobi, Antibiotic For Lung Infections
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Israel Approves Tobi, Antibiotic For Lung Infections

SEATTLE, WA -- January 5, 2000 -- PathoGenesis Corp. today announced that its drug Tobi(R) (tobramycin solution for inhalation) has received marketing clearance from the Ministry of Health in Israel. The drug is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections.

"We're delighted to add Israel to our growing list of international markets," said Wilbur H. Gantz, chairman and chief executive officer of PathoGenesis. "Tobi is an important addition to the physicians' arsenal of drugs to manage serious lung infections in their cystic fibrosis patients."

In Israel, Tobi will be distributed by Teva Pharmaceutical Industries Ltd. An estimated 400 people in Israel have cystic fibrosis, a serious genetic disease that primarily affects Caucasians. Tobi is designed for these patients to take at home in repeated cycles of 28 days on drug, 28 days off drug. It is inhaled twice daily and requires about 15 minutes each time.

Related Links: Tobi (tobramycin), PathoGenesis Corp. and Teva Pharmaceutical Industries Ltd.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities